Loading...
Please wait, while we are loading the content...
Similar Documents
A randomized trial of pegylated-interferon-?2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin
| Content Provider | Scilit |
|---|---|
| Author | Ciancio, A. Picciotto, A. Giordanino, C. Smedile, A. Tabone, M. Manca, A. Marenco, G. Garbagnoli, P. Andreoni, Massimo Cariti, G. Calleri, G. Sartori, M. Cusumano, S. Grasso, A. Rizzi, R. Gallo, M. Basso, M. Anselmo, M. Percario, G. Ciccone, Giovannino Rizzetto, M. Saracco, Giorgio Maria |
| Copyright Year | 2006 |
| Description | Journal: Alimentary Pharmacology & Therapeutics BACKGROUND: There is yet no established treatment for chronic hepatitis C patients non-responder to standard interferon and ribavirin. AIM: To evaluate efficacy and safety of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in such patients. METHODS: 161 non-responders to standard interferon and ribavirin were randomized into two groups: 81 patients (Group 1) were given weekly Peg-IFN-alpha2a 180 microg plus ribavirin 1,000-1,200 mg/daily for 12 months, 80 patients (Group 2) received weekly Peg-IFN-alpha2a 180 microg plus ribavirin 1,000-1,200 mg/daily and amantadine 200 mg/daily for 12 months. RESULTS: At the end of follow-up, HCV-RNA was negative in 29.6% of Group 1 and in 21.2% of Group 2 patients (P = 0.22). Patients with genotypes 1 and 4 responded better to bi-therapy (21.7%) than to triple therapy (17.3%, P = 0.5) while among patients with genotypes 2 and 3 there was a trend towards a higher sustained virological response rate when retreated with triple treatment (80% vs. 75%, P = 0.82). On multivariate analysis, genotype 1 or 4, high body mass index and >20% reduction of Peg-interferon were associated with the treatment failure. CONCLUSIONS: The addition of amantadine does not improve the overall SVR rate in non-responder patients retreated with Peg-IFN and ribavirin; however, about 30% of non-responders may achieve a sustained response, in particular patients with genotypes 2 and 3 show a high SVR (75%) |
| Related Links | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2006.03098.x/pdf |
| Ending Page | 1086 |
| Page Count | 8 |
| Starting Page | 1079 |
| e-ISSN | 13652036 |
| DOI | 10.1111/j.1365-2036.2006.03098.x |
| Journal | Alimentary Pharmacology & Therapeutics |
| Issue Number | 7 |
| Volume Number | 24 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2006-10-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Alimentary Pharmacology & Therapeutics Gastroenterology and Hepatology Randomized Trial |
| Content Type | Text |
| Resource Type | Article |
